Identification

Name
Amphetamine
Accession Number
DB00182  (APRD00480)
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Description

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. By mimicking the structures of the catecholamine neurotransmitters, noradrenaline and dopamine, amphetamines modulate monoamine release, reuptake, and signalling within the brain. Although "amphetamine" is used as a descriptor of its own structural class, amphetamine properly refers to a racemic free base composed of equal parts of its two optical antipodes: levo-amphetamine and dextro-amphetamine. Used in the past for the treatment of depression, stress, and for concentration improvement, it is currently available as a prescription drug for the treatment of attention hyperactivity disorder (ADHD), narcolepsy, and as an adjunct in the treatment of exogenous obesity. Amphetamine is also available in a mixed salt/mixed enantiomer form (Adderall), where d-amphetamine and l-amphetamine are available in a ratio of 3:1. It is also available in a prodrug form as lisdexamfetamine.

Structure
Thumb
Synonyms
  • 1-phenyl-2-aminopropane
  • 1-Phenylpropan-2-amin
  • alpha-Methylbenzeneethaneamine
  • alpha-Methylphenylethylamine
  • Amfetamine
  • Amfetaminum
  • Amphetamin
  • Amphetamine
  • beta-Aminopropylbenzene
  • beta-Phenylisopropylamin
  • beta-Phenylisopropylamine
  • Desoxynorephedrine
  • rac-(2R)-1-phenylpropan-2-amine
  • rac-amphetamine
  • α-methylbenzeneethaneamine
  • α-methylphenethylamine
  • β-aminopropylbenzene
  • β-phenylisopropylamine
Product Ingredients
IngredientUNIICASInChI Key
Amphetamine adipateZ58RH02W4M64770-51-0OFCJKOOVFDGTLY-UHFFFAOYSA-N
Amphetamine aspartateH527KAP6L525333-81-7OJNSNSZTGUACNI-VAGRMJETSA-N
Amphetamine aspartate monohydrateO1ZPV620O4851591-76-9DAWXRFCLWKUCNS-MNTSKLTCSA-N
Amphetamine sulfate6DPV8NK46S60-13-9PYHRZPFZZDCOPH-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adzenys ERSuspension, extended release1.25 mg/mLOralNeos Therapeutics, Lp2017-09-16Not applicableUs
Adzenys XR-ODTTablet, orally disintegrating3.1 mg/1OralNeos Therapeutics, Lp2016-02-16Not applicableUs
Adzenys XR-ODTTablet, orally disintegrating18.8 mg/1OralNeos Therapeutics, Lp2016-02-16Not applicableUs
Adzenys XR-ODTTablet, orally disintegrating9.4 mg/1OralNeos Therapeutics, Lp2016-02-16Not applicableUs
Adzenys XR-ODTTablet, orally disintegrating15.7 mg/1OralNeos Therapeutics, Lp2016-02-16Not applicableUs
Adzenys XR-ODTTablet, orally disintegrating6.3 mg/1OralNeos Therapeutics, Lp2016-02-16Not applicableUs
Adzenys XR-ODTTablet, orally disintegrating12.5 mg/1OralNeos Therapeutics, Lp2016-02-16Not applicableUs
Dyanavel XRSuspension, extended release2.5 mg/mLOralTris Pharma, Inc.2015-10-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EvekeoTablet5 mg/1OralArbor Pharmaceuticals2015-02-012017-09-30Us
EvekeoTablet5 mg/1OralArbor Pharmaceuticals2015-11-01Not applicableUs
EvekeoTablet10 mg/1OralArbor Pharmaceuticals2015-02-012017-10-11Us
EvekeoTablet10 mg/1OralArbor Pharmaceuticals2015-11-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Amphetamine XRAmphetamine aspartate monohydrate (6.25 mg) + Amphetamine sulfate (6.25 mg) + Dextroamphetamine saccharate (6.25 mg) + Dextroamphetamine sulfate (6.25 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (3.75 mg) + Amphetamine sulfate (3.75 mg) + Dextroamphetamine saccharate (3.75 mg) + Dextroamphetamine sulfate (3.75 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (7.5 mg) + Amphetamine sulfate (7.5 mg) + Dextroamphetamine saccharate (7.5 mg) + Dextroamphetamine sulfate (7.5 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (1.25 mg) + Amphetamine sulfate (1.25 mg) + Dextroamphetamine saccharate (1.25 mg) + Dextroamphetamine sulfate (1.25 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (6.25 mg) + Amphetamine sulfate (6.25 mg) + Dextroamphetamine saccharate (6.25 mg) + Dextroamphetamine sulfate (6.25 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (2.5 mg) + Amphetamine sulfate (2.5 mg) + Dextroamphetamine saccharate (2.5 mg) + Dextroamphetamine sulfate (2.5 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (5 mg) + Amphetamine sulfate (5 mg) + Dextroamphetamine saccharate (5 mg) + Dextroamphetamine sulfate (5 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (7.5 mg) + Amphetamine sulfate (7.5 mg) + Dextroamphetamine saccharate (7.5 mg) + Dextroamphetamine sulfate (7.5 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (1.25 mg) + Amphetamine sulfate (1.25 mg) + Dextroamphetamine saccharate (1.25 mg) + Dextroamphetamine sulfate (1.25 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Act Amphetamine XRAmphetamine aspartate monohydrate (3.75 mg) + Amphetamine sulfate (3.75 mg) + Dextroamphetamine saccharate (3.75 mg) + Dextroamphetamine sulfate (3.75 mg)Capsule, extended releaseOralTeva2015-10-02Not applicableCanada
Categories
UNII
CK833KGX7E
CAS number
300-62-9
Weight
Average: 135.2062
Monoisotopic: 135.104799421
Chemical Formula
C9H13N
InChI Key
KWTSXDURSIMDCE-UHFFFAOYSA-N
InChI
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
IUPAC Name
1-phenylpropan-2-amine
SMILES
CC(N)CC1=CC=CC=C1

Pharmacology

Indication

For treatment of Attention Deficit Disorder with Hyperactivity (ADDH), narcolepsy, and exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Amphetamines stimulate the release of norepinephrine from central adrenergic receptors. At higher dosages, they cause release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems. Amphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect. The drug interacts with VMAT enzymes to enhance release of DA and 5-HT from vesicles. It may also directly cause the reversal of DAT and SERT.

TargetActionsOrganism
ASynaptic vesicular amine transporter
inhibitor
Human
ASodium-dependent dopamine transporter
negative modulator
Human
ACocaine- and amphetamine-regulated transcript protein
agonist
Human
ATrace amine-associated receptor 1
agonist
Human
USodium-dependent noradrenaline transporter
stimulator
Human
UAlpha adrenergic receptor
agonist
Human
UBeta adrenergic receptor
agonist
Human
UD(2) dopamine receptor
binder
Human
UAmine oxidase [flavin-containing] BNot AvailableHuman
USodium-dependent serotonin transporter
binder
Human
AMonoamine oxidase
inhibitor
Human
Avesicular monoamine transporter 2 (VMAT2)Not AvailableHuman
Absorption

Amphetamine forms easily absorbed molecules that are highly lipid soluble. D-amphetamine mean peak plasma concentrations of 44.9 ng/mL occurred at a median time of 5.0 hours after dosing, and L-amphetamine mean peak plasma concentrations of 14.5 ng/mL occurred at a median time of 5.25 hours after dosing.

Volume of distribution
Not Available
Protein binding

15-40%

Metabolism

Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4-hydroxyamphetamine, or on the side chain α or β carbons to form alpha-hydroxy-amphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.

Route of elimination

With normal urine pHs, approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30-40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9 .9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion.

Half life

The half life for adults in the fasted state was found to be 11.25 hr.

Clearance
Not Available
Toxicity

LD50=180 mg/kg(subcutaneous injection in rat). The most common presenting symptoms seen are agitation, hallucinations, suicidal behaviour, and chest pain.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Amphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Amphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Amphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Amphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Amphetamine.Experimental
AbirateroneThe serum concentration of Amphetamine can be increased when it is combined with Abiraterone.Approved
AcarboseAmphetamine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Amphetamine is combined with Acebutolol.Approved, Investigational
AcepromazineAcepromazine may decrease the stimulatory activities of Amphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Amphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Amphetamine.Approved
AcrivastineAmphetamine may decrease the sedative activities of Acrivastine.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Amphetamine.Experimental
AlbiglutideAmphetamine may increase the hypoglycemic activities of Albiglutide.Approved
AlcaftadineAmphetamine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amphetamine.Approved, Illicit
AlimemazineAmphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AliskirenAmphetamine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmasilateAlmasilate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Experimental
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Amphetamine.Approved, Investigational
AlogliptinAmphetamine may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amphetamine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Amphetamine.Illicit
AlprenololAmphetamine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Amphetamine.Approved
AluminiumAluminium may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Investigational
AmbrisentanAmphetamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineAmphetamine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneThe metabolism of Amphetamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may decrease the stimulatory activities of Amphetamine.Approved, Investigational
AmitriptylineAmphetamine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineAmphetamine may increase the hypotensive activities of Amlodipine.Approved
Ammonium chlorideThe serum concentration of Amphetamine can be decreased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AmoxapineAmphetamine may increase the serotonergic activities of Amoxapine.Approved
AmperozideAmperozide may decrease the stimulatory activities of Amphetamine.Experimental
AntazolineAmphetamine may decrease the sedative activities of Antazoline.Approved
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Amphetamine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may decrease the stimulatory activities of Amphetamine.Approved, Investigational
ArtemetherThe metabolism of Amphetamine can be decreased when combined with Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Amphetamine resulting in a loss in efficacy.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Amphetamine.Approved
AstemizoleAmphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtenololAmphetamine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineAmphetamine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineAmphetamine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneAzaperone may decrease the stimulatory activities of Amphetamine.Investigational, Vet Approved
AzatadineAmphetamine may decrease the sedative activities of Azatadine.Approved
AzelastineAmphetamine may decrease the sedative activities of Azelastine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Bambuterol.Approved, Investigational
BamipineAmphetamine may decrease the sedative activities of Bamipine.Experimental
BenazeprilAmphetamine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideAmphetamine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Amphetamine is combined with Benmoxin.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Amphetamine.Approved, Investigational
BenzatropineAmphetamine may decrease the sedative activities of Benzatropine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Amphetamine.Approved, Illicit
BepridilAmphetamine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Amphetamine.Approved, Investigational
BetaxololThe metabolism of Amphetamine can be decreased when combined with Betaxolol.Approved, Investigational
BethanidineAmphetamine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Amphetamine is combined with Bezafibrate.Approved, Investigational
BezitramideAmphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BietaserpineAmphetamine may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxBifeprunox may decrease the stimulatory activities of Amphetamine.Investigational
BimatoprostAmphetamine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Investigational
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Experimental
BisoprololAmphetamine may increase the hypotensive activities of Bisoprolol.Approved
BosentanAmphetamine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Amphetamine may increase the hypotensive activities of BQ-123.Investigational
BretyliumAmphetamine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Amphetamine.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Brimonidine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Amphetamine.Approved, Investigational
BromperidolBromperidol may decrease the stimulatory activities of Amphetamine.Approved, Investigational
BrompheniramineAmphetamine may decrease the sedative activities of Brompheniramine.Approved
BucindololThe risk or severity of adverse effects can be increased when Amphetamine is combined with Bucindolol.Investigational
BuclizineAmphetamine may decrease the sedative activities of Buclizine.Approved
BupranololAmphetamine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amphetamine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Amphetamine is combined with Bupropion.Approved
BupropionThe metabolism of Amphetamine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Amphetamine is combined with Buspirone.Approved, Investigational
ButaperazineButaperazine may decrease the stimulatory activities of Amphetamine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amphetamine.Approved, Illicit, Vet Approved
Butyric AcidAmphetamine may decrease the sedative activities of Butyric Acid.Experimental, Investigational
CabergolineThe metabolism of Cabergoline can be decreased when combined with Amphetamine.Approved
CadralazineAmphetamine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineAmphetamine may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Investigational
Calcium silicateCalcium silicate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Experimental
CanagliflozinAmphetamine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanAmphetamine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilAmphetamine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilAmphetamine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilAmphetamine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amphetamine.Approved, Investigational
CarbinoxamineAmphetamine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amphetamine.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Amphetamine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Amphetamine is combined with Caroxazone.Withdrawn
CarteololAmphetamine may increase the hypotensive activities of Carteolol.Approved
CarvedilolAmphetamine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Amphetamine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Amphetamine is combined with Celiprolol.Approved, Investigational
CetirizineAmphetamine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineAmphetamine may decrease the sedative activities of Chloropyramine.Approved
ChloroquineThe metabolism of Amphetamine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideAmphetamine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineAmphetamine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineAmphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Amphetamine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Amphetamine.Experimental
ChlorpromazineThe metabolism of Amphetamine can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideAmphetamine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Amphetamine.Approved, Investigational, Withdrawn
ChlorthalidoneAmphetamine may increase the hypotensive activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Amphetamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineAmphetamine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilAmphetamine may increase the hypotensive activities of Cilazapril.Approved
CimetidineThe metabolism of Amphetamine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Amphetamine can be decreased when combined with Cinacalcet.Approved
CinnarizineAmphetamine may decrease the sedative activities of Cinnarizine.Approved, Investigational
CirazolineAmphetamine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Amphetamine.Approved
ClemastineAmphetamine may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobazamThe metabolism of Amphetamine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineAmphetamine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineAmphetamine may increase the hypotensive activities of Clonidine.Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Amphetamine.Experimental
CloranololAmphetamine may increase the hypotensive activities of Cloranolol.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Amphetamine.Experimental
ClotrimazoleThe metabolism of Amphetamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Amphetamine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Amphetamine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Amphetamine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amphetamine.Approved, Illicit
CryptenamineAmphetamine may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineCyamemazine may decrease the stimulatory activities of Amphetamine.Approved
CyclizineAmphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Amphetamine.Approved
CyclopenthiazideAmphetamine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideAmphetamine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineAmphetamine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinAmphetamine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Amphetamine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amphetamine.Investigational
DarifenacinThe metabolism of Amphetamine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Amphetamine can be increased when it is combined with Darunavir.Approved
DebrisoquinAmphetamine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilAmphetamine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Amphetamine can be decreased when combined with Delavirdine.Approved
DeserpidineAmphetamine may increase the hypotensive activities of Deserpidine.Approved
DesipramineAmphetamine may increase the serotonergic activities of Desipramine.Approved, Investigational
DesloratadineAmphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amphetamine.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineAmphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineAmphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateAmphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DexlansoprazoleDexlansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DexmethylphenidateAmphetamine may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DexrabeprazoleDexrabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Experimental
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Amphetamine.Approved, Illicit
DextromethorphanAmphetamine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amphetamine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amphetamine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amphetamine.Approved, Investigational
DiazoxideAmphetamine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinAmphetamine may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Investigational
DiethylnorspermineAmphetamine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionAmphetamine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineAmphetamine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amphetamine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Amphetamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amphetamine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amphetamine.Experimental, Illicit
DiltiazemAmphetamine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimenhydrinateAmphetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneAmphetamine may decrease the sedative activities of Dimetindene.Approved, Investigational
DimetotiazineAmphetamine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineThe metabolism of Amphetamine can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amphetamine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Amphetamine is combined with Dipivefrin.Approved
DisopyramideAmphetamine may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Amphetamine is combined with Disulfiram.Approved
DixyrazineDixyrazine may decrease the stimulatory activities of Amphetamine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Amphetamine is combined with Domperidone.Approved, Investigational, Vet Approved
DopamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Dopamine.Approved
DorzolamideAmphetamine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinAmphetamine may increase the serotonergic activities of Dosulepin.Approved
DoxapramAmphetamine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinAmphetamine may increase the hypotensive activities of Doxazosin.Approved
DoxepinAmphetamine may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Doxofylline.Approved, Investigational
DoxylamineAmphetamine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Amphetamine.Experimental
DronabinolDronabinol may increase the tachycardic activities of Amphetamine.Approved, Illicit
DronedaroneThe metabolism of Amphetamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may decrease the stimulatory activities of Amphetamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amphetamine.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Amphetamine is combined with Droxidopa.Approved, Investigational
DulaglutideAmphetamine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amphetamine.Approved
EbastineAmphetamine may decrease the sedative activities of Ebastine.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amphetamine.Experimental, Illicit
EcopipamEcopipam may decrease the stimulatory activities of Amphetamine.Investigational
EfonidipineAmphetamine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Amphetamine.Approved, Investigational
EliglustatThe metabolism of Amphetamine can be decreased when combined with Eliglustat.Approved
EmedastineAmphetamine may decrease the sedative activities of Emedastine.Approved
EmpagliflozinAmphetamine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilAmphetamine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAmphetamine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineAmphetamine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Amphetamine.Approved, Investigational
EpanololThe risk or severity of adverse effects can be increased when Amphetamine is combined with Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Amphetamine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Ephedrine.Approved
EpinastineAmphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineAmphetamine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolAmphetamine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAmphetamine may increase the hypotensive activities of Eprosartan.Approved
ErgotamineAmphetamine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amphetamine.Approved, Investigational
EsmirtazapineAmphetamine may increase the serotonergic activities of Esmirtazapine.Investigational
EsomeprazoleEsomeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Amphetamine.Approved
EthopropazineAmphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideAmphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amphetamine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Etilefrine.Withdrawn
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Amphetamine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amphetamine.Illicit, Vet Approved
ExenatideAmphetamine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FamotidineAmphetamine may decrease the sedative activities of Famotidine.Approved
FelodipineAmphetamine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineFencamfamine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Withdrawn
FenfluramineAmphetamine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamAmphetamine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Amphetamine is combined with Fenozolone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amphetamine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidAmphetamine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amphetamine.Approved
FexofenadineAmphetamine may decrease the sedative activities of Fexofenadine.Approved, Investigational
FluanisoneFluanisone may decrease the stimulatory activities of Amphetamine.Experimental
FlunarizineAmphetamine may decrease the sedative activities of Flunarizine.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amphetamine.Approved, Vet Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Amphetamine.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Amphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Amphetamine.Approved, Investigational
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amphetamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Formoterol.Approved, Investigational
FosinoprilAmphetamine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Amphetamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Amphetamine.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Amphetamine.Experimental
GliclazideAmphetamine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAmphetamine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAmphetamine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
Glutamic AcidThe serum concentration of Amphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GlyburideAmphetamine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzAmphetamine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelAmphetamine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineAmphetamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineAmphetamine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineAmphetamine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorAmphetamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzAmphetamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanAmphetamine may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Amphetamine can be decreased when combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amphetamine.Approved, Illicit, Investigational
HexamethoniumAmphetamine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Hydracarbazine.Experimental
HydralazineAmphetamine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideAmphetamine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amphetamine.Approved, Illicit
HydroflumethiazideAmphetamine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amphetamine.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Experimental, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Amphetamine.Approved
HydroxyzineAmphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Amphetamine.Approved
ImidaprilAmphetamine may increase the hypotensive activities of Imidapril.Investigational
ImipramineAmphetamine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Amphetamine.Investigational, Withdrawn
IndapamideAmphetamine may increase the hypotensive activities of Indapamide.Approved
IndenololAmphetamine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Amphetamine can be decreased when combined with Indinavir.Approved
IndoraminAmphetamine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartAmphetamine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirAmphetamine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineAmphetamine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineAmphetamine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanAmphetamine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproAmphetamine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Amphetamine.Approved, Investigational
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Amphetamine.Approved
Ioflupane I-123Amphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleAmphetamine may increase the serotonergic activities of Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Amphetamine is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Amphetamine.Withdrawn
IrbesartanAmphetamine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Amphetamine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Amphetamine is combined with Isometheptene.Approved
IsoniazidThe metabolism of Amphetamine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Isoprenaline.Approved, Investigational
IsothipendylAmphetamine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineAmphetamine may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinAmphetamine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amphetamine.Approved, Investigational
KetoconazoleThe metabolism of Amphetamine can be decreased when combined with Ketoconazole.Approved, Investigational
KetotifenAmphetamine may decrease the sedative activities of Ketotifen.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Amphetamine.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Labetalol.Approved
LacidipineAmphetamine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LafutidineAmphetamine may decrease the sedative activities of Lafutidine.Investigational
LansoprazoleLansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
LatanoprostAmphetamine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LavoltidineAmphetamine may decrease the sedative activities of Lavoltidine.Investigational
LercanidipineAmphetamine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevocabastineAmphetamine may decrease the sedative activities of Levocabastine.Approved, Investigational
LevocetirizineAmphetamine may decrease the sedative activities of Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Amphetamine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amphetamine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Amphetamine.Approved, Investigational
LevonordefrinAmphetamine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amphetamine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Amphetamine is combined with Linezolid.Approved, Investigational
LinsidomineAmphetamine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideAmphetamine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Amphetamine.Approved, Investigational
LisinoprilAmphetamine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Amphetamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Amphetamine is combined with Lithium.Approved
LodoxamideAmphetamine may decrease the sedative activities of Lodoxamide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Amphetamine.Illicit
LofepramineAmphetamine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineAmphetamine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Amphetamine can be decreased when combined with Lopinavir.Approved
LoratadineAmphetamine may decrease the sedative activities of Loratadine.Approved, Investigational
LorcaserinThe metabolism of Amphetamine can be decreased when combined with Lorcaserin.Approved
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Amphetamine.Approved
LosartanAmphetamine may increase the hypotensive activities of Losartan.Approved
LoxapineLoxapine may decrease the stimulatory activities of Amphetamine.Approved
LumefantrineThe metabolism of Amphetamine can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Amphetamine.Approved, Investigational
MacitentanAmphetamine may increase the hypotensive activities of Macitentan.Approved
MagaldrateMagaldrate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Investigational
Magnesium oxideMagnesium oxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved
ManidipineThe metabolism of Amphetamine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mebanazine.Withdrawn
MecamylamineAmphetamine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminAmphetamine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineAmphetamine may decrease the sedative activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mefenorex.Experimental
MelperoneMelperone may decrease the stimulatory activities of Amphetamine.Approved, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Amphetamine.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Amphetamine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Amphetamine.Experimental
MepyramineAmphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineAmphetamine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Amphetamine.Approved, Investigational
MetaraminolAmphetamine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminAmphetamine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Amphetamine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amphetamine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Amphetamine.Approved, Illicit
MethapyrileneAmphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of Amphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethoserpidineAmphetamine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Amphetamine can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethoxamineAmphetamine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Amphetamine.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Amphetamine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amphetamine.Experimental
Methylene blueAmphetamine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateAmphetamine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetiamideAmphetamine may decrease the sedative activities of Metiamide.Experimental
MetipranololAmphetamine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneAmphetamine may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amphetamine.Approved, Investigational
MetyrosineAmphetamine may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mianserin.Approved, Investigational
MibefradilAmphetamine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineAmphetamine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Amphetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Amphetamine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneAmphetamine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolAmphetamine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Amphetamine.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Amphetamine.Approved
MinoxidilAmphetamine may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirabegronThe metabolism of Amphetamine can be decreased when combined with Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mirtazapine.Approved
MizolastineAmphetamine may decrease the sedative activities of Mizolastine.Investigational
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Amphetamine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Amphetamine is combined with Moclobemide.Approved, Investigational
MoexiprilAmphetamine may increase the hypotensive activities of Moexipril.Approved
MolindoneMolindone may decrease the stimulatory activities of Amphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of Amphetamine.Experimental
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Amphetamine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Amphetamine.Experimental
MoxonidineAmphetamine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineAmphetamine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the tachycardic activities of Amphetamine.Approved, Investigational
NadololAmphetamine may increase the hypotensive activities of Nadolol.Approved
NaftopidilAmphetamine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amphetamine.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Amphetamine.Investigational
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Amphetamine.Approved, Investigational
NateglinideAmphetamine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololAmphetamine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amphetamine.Approved, Withdrawn
NevirapineThe metabolism of Amphetamine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Amphetamine.Withdrawn
NicardipineThe metabolism of Amphetamine can be decreased when combined with Nicardipine.Approved, Investigational
NicomorphineAmphetamine may increase the analgesic activities of Nicomorphine.Experimental
NicorandilAmphetamine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineAmphetamine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Amphetamine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineAmphetamine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineAmphetamine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineAmphetamine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineAmphetamine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideAmphetamine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NizatidineAmphetamine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineAmphetamine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Amphetamine.Approved, Illicit
NortriptylineAmphetamine may increase the serotonergic activities of Nortriptyline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Amphetamine is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Amphetamine is combined with Octamoxin.Withdrawn
OlanzapineAmphetamine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanAmphetamine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Olodaterol.Approved
OlopatadineAmphetamine may decrease the sedative activities of Olopatadine.Approved
OmapatrilatAmphetamine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleOmeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational, Vet Approved
OndansetronOndansetron may decrease the stimulatory activities of Amphetamine.Approved
OpipramolAmphetamine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Amphetamine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Orciprenaline.Approved
OsanetantOsanetant may decrease the stimulatory activities of Amphetamine.Investigational
OxatomideAmphetamine may decrease the sedative activities of Oxatomide.Investigational
OxprenololAmphetamine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Amphetamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amphetamine.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Amphetamine.Experimental
OzagrelAmphetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Amphetamine.Approved
PanobinostatThe serum concentration of Amphetamine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazolePantoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
PargylineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amphetamine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Amphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PemirolastAmphetamine may decrease the sedative activities of Pemirolast.Approved, Investigational
PenbutololAmphetamine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Amphetamine.Experimental
PentamidineAmphetamine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amphetamine.Approved, Vet Approved
PentoliniumAmphetamine may increase the hypotensive activities of Pentolinium.Approved
PerazinePerazine may decrease the stimulatory activities of Amphetamine.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Amphetamine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilAmphetamine may increase the hypotensive activities of Perindopril.Approved
PerospironePerospirone may decrease the stimulatory activities of Amphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Amphetamine.Approved
PethidineAmphetamine may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Amphetamine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Amphetamine.Approved
PhenindamineAmphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Pheniprazine.Withdrawn
PheniramineAmphetamine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Phenmetrazine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Amphetamine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Amphetamine.Experimental
PhenoxybenzamineAmphetamine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Amphetamine.Approved, Illicit
PhentolamineAmphetamine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineAmphetamine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Amphetamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Amphetamine.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Amphetamine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Amphetamine.Investigational
PimozidePimozide may decrease the stimulatory activities of Amphetamine.Approved
PinacidilAmphetamine may increase the hypotensive activities of Pinacidil.Approved
PindololAmphetamine may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneAmphetamine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperonePipamperone may decrease the stimulatory activities of Amphetamine.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Amphetamine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Amphetamine.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Amphetamine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Amphetamine.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Pivhydrazine.Withdrawn
PizotifenAmphetamine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorAmphetamine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideAmphetamine may increase the hypotensive activities of Polythiazide.Approved
PramlintideAmphetamine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinAmphetamine may increase the hypotensive activities of Prazosin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Prenalterol.Experimental
ProcarbazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Amphetamine.Approved, Vet Approved
PromazineThe metabolism of Amphetamine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineAmphetamine may decrease the sedative activities of Promethazine.Approved, Investigational
PropericiazinePropericiazine may decrease the stimulatory activities of Amphetamine.Approved, Investigational
PropranololAmphetamine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of Amphetamine.Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Protokylol.Approved, Vet Approved
ProtriptylineAmphetamine may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Amphetamine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Amphetamine.Approved
QuifenadineAmphetamine may decrease the sedative activities of Quifenadine.Experimental
QuinaprilAmphetamine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe metabolism of Amphetamine can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Amphetamine can be decreased when combined with Quinine.Approved
RabeprazoleRabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RacepinephrineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Amphetamine.Investigational
RamiprilAmphetamine may increase the hypotensive activities of Ramipril.Approved
RanitidineAmphetamine may decrease the sedative activities of Ranitidine.Approved
RanolazineThe metabolism of Amphetamine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Amphetamine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amphetamine.Approved
RemikirenAmphetamine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Amphetamine.Approved, Withdrawn
RepaglinideAmphetamine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineAmphetamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Reserpine.Approved, Investigational
RilmenidineAmphetamine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatAmphetamine may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Amphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Amphetamine.Investigational
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Amphetamine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Amphetamine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Amphetamine.Approved
RolapitantThe metabolism of Amphetamine can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Amphetamine.Approved, Investigational
RosiglitazoneAmphetamine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
Roxatidine acetateAmphetamine may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
RucaparibThe metabolism of Amphetamine can be decreased when combined with Rucaparib.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Salmeterol.Approved
SaprisartanAmphetamine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinAmphetamine may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagAmphetamine may increase the hypotensive activities of Selexipag.Approved
SertindoleSertindole may decrease the stimulatory activities of Amphetamine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amphetamine.Approved
SitagliptinAmphetamine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanAmphetamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved
SpiraprilAmphetamine may increase the hypotensive activities of Spirapril.Approved
StiripentolThe metabolism of Amphetamine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amphetamine.Approved, Investigational
SulfadiazineAmphetamine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleAmphetamine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleAmphetamine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may decrease the stimulatory activities of Amphetamine.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Amphetamine.Experimental
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Amphetamine.Approved, Investigational
SunitinibAmphetamine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SynephrineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Synephrine.Experimental
TalinololAmphetamine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Amphetamine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Amphetamine.Approved
TelmisartanAmphetamine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilAmphetamine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Amphetamine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Terbutaline.Approved
TerfenadineAmphetamine may decrease the sedative activities of Terfenadine.Approved, Withdrawn
TerlipressinAmphetamine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneAmphetamine may decrease the sedative activities of Tesmilifene.Investigational
Testosterone propionateThe risk or severity of adverse effects can be increased when Testosterone propionate is combined with Amphetamine.Approved, Investigational, Vet Approved, Withdrawn
TetrabenazineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Tetrabenazine.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Amphetamine.Investigational
TetryzolineAmphetamine may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineAmphetamine may increase the hypotensive activities of Theodrenaline.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of Amphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Amphetamine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amphetamine.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Amphetamine.Approved
ThonzylamineAmphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Amphetamine.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Amphetamine.Approved, Investigational
TiboloneAmphetamine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Amphetamine can be decreased when combined with Ticlopidine.Approved
TicrynafenAmphetamine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Amphetamine.Experimental
TimololAmphetamine may increase the hypotensive activities of Timolol.Approved
TipranavirThe metabolism of Amphetamine can be decreased when combined with Tipranavir.Approved, Investigational
TolazamideAmphetamine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineAmphetamine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideAmphetamine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amphetamine.Approved, Withdrawn
TolonidineAmphetamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Amphetamine.Approved
TorasemideAmphetamine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Amphetamine.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Tramazoline.Investigational
TrandolaprilAmphetamine may increase the hypotensive activities of Trandolapril.Approved
TranilastAmphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Tranylcypromine.Approved, Investigational
TravoprostAmphetamine may increase the hypotensive activities of Travoprost.Approved
TrazodoneAmphetamine may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilAmphetamine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Tretoquinol.Experimental
TrichlormethiazideAmphetamine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Amphetamine.Approved, Investigational
TrifluperidolTrifluperidol may decrease the stimulatory activities of Amphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Amphetamine.Approved, Vet Approved
TrimazosinAmphetamine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanAmphetamine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineAmphetamine may increase the serotonergic activities of Trimipramine.Approved
TripelennamineAmphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineAmphetamine may decrease the sedative activities of Triprolidine.Approved
TritoqualineAmphetamine may decrease the sedative activities of Tritoqualine.Experimental
TromethamineTromethamine may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved
TyramineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Tyramine.Investigational, Nutraceutical
UnoprostoneAmphetamine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilAmphetamine may increase the hypotensive activities of Urapidil.Investigational
ValsartanAmphetamine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Amphetamine.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Amphetamine.Experimental
VilanterolThe risk or severity of adverse effects can be increased when Amphetamine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Amphetamine.Approved
VincamineAmphetamine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineAmphetamine may increase the hypotensive activities of Vinpocetine.Investigational
Vitamin CThe serum concentration of Amphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Amphetamine.Approved, Investigational
XipamideAmphetamine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineAmphetamine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Amphetamine.Withdrawn
ZiprasidoneThe metabolism of Amphetamine can be decreased when combined with Ziprasidone.Approved
ZofenoprilAmphetamine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Amphetamine.Approved, Investigational
ZotepineZotepine may decrease the stimulatory activities of Amphetamine.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Amphetamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Guohong Wang, "Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples." U.S. Patent US20020090661, issued July 11, 2002.

US20020090661
General References
  1. Leith NJ, Kuczenski R: Chronic amphetamine: tolerance and reverse tolerance reflect different behavioral actions of the drug. Pharmacol Biochem Behav. 1981 Sep;15(3):399-404. [PubMed:7291243]
  2. Chaudhry IA, Turkanis SA, Karler R: Characteristics of "reverse tolerance" to amphetamine-induced locomotor stimulation in mice. Neuropharmacology. 1988 Aug;27(8):777-81. [PubMed:3216957]
  3. Sax KW, Strakowski SM: Behavioral sensitization in humans. J Addict Dis. 2001;20(3):55-65. [PubMed:11681593]
  4. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  5. Heal DJ, Smith SL, Gosden J, Nutt DJ: Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol. 2013 Jun;27(6):479-96. doi: 10.1177/0269881113482532. Epub 2013 Mar 28. [PubMed:23539642]
External Links
Human Metabolome Database
HMDB0014328
KEGG Drug
D07445
KEGG Compound
C07514
PubChem Compound
3007
PubChem Substance
46506414
ChemSpider
13852819
BindingDB
50005246
ChEBI
132233
ChEMBL
CHEMBL405
Therapeutic Targets Database
DAP001146
PharmGKB
PA448408
IUPHAR
2147
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Amphetamine
ATC Codes
N06BA01 — Amfetamine
FDA label
Download (10.4 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingBasic ScienceHealthy Volunteers1
0Not Yet RecruitingOtherCardiovascular System / Hemodynamics1
1CompletedNot AvailableHealthy Volunteers1
1CompletedOtherHealthy Volunteers1
1, 2RecruitingTreatmentDependence, Cocaine1
2Active Not RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Deficient Emotional Self-Regulation (DESR)1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity2
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
2Not Yet RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Autism Spectrum Conditions/Disorders1
2RecruitingTreatmentStrokes1
2, 3CompletedTreatmentCognitive Impairments / Disseminated Sclerosis / Impaired Processing Speed1
2, 3CompletedTreatmentDependence, Cocaine1
2, 3RecruitingTreatmentDisseminated Sclerosis1
3Active Not RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)2
4CompletedBasic ScienceEating Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)3
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Deficient Emotional Self-Regulation (DESR)1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Reading Disability1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4Not Yet RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
4RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableActive Not RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableCompletedNot AvailableHealthy Volunteers / Nicotine Dependence1
Not AvailableCompletedNot AvailableNicotine Dependence1
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity1
Not AvailableCompletedTreatmentStrokes1
Not AvailableNot Yet RecruitingNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD) / Problem Behavior1
Not AvailableRecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)2
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
  • Lannett co inc
  • Akorn inc
  • Teva pharmaceuticals usa inc
Packagers
  • Barr Pharmaceuticals
  • Cambridge Isotope Laboratories Inc.
  • DSM Corp.
  • Eon Labs
  • GlaxoSmithKline Inc.
  • Lundbeck Inc.
  • Physicians Total Care Inc.
  • Shire Inc.
Dosage forms
FormRouteStrength
Capsule, extended releaseOral
Suspension, extended releaseOral1.25 mg/mL
Tablet, orally disintegratingOral12.5 mg/1
Tablet, orally disintegratingOral15.7 mg/1
Tablet, orally disintegratingOral18.8 mg/1
Tablet, orally disintegratingOral3.1 mg/1
Tablet, orally disintegratingOral6.3 mg/1
Tablet, orally disintegratingOral9.4 mg/1
CapsuleOral
TabletOral
Suspension, extended releaseOral2.5 mg/mL
TabletOral10 mg/1
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Desoxyn 5 mg tablet5.1USD tablet
Dexedrine 15 mg 24 Hour Capsule4.22USD capsule
Dexedrine 10 mg 24 Hour Capsule3.23USD capsule
Dexedrine 5 mg 24 Hour Capsule3.0USD capsule
Dexedrine spansule 15 mg2.45USD each
Dexedrine spansule 10 mg1.91USD each
Dexedrine spansule 5 mg1.91USD each
Amphetamine salts 12.5 mg tablet1.43USD tablet
Amphetamine salts 15 mg tablet1.43USD tablet
Amphetamine salts 7.5 mg tablet1.43USD tablet
Amphetamine salts 10 mg tablet1.37USD tablet
Amphetamine salts 20 mg tablet1.37USD tablet
Amphetamine salts 30 mg tablet1.37USD tablet
Amphetamine salts 5 mg tablet1.37USD tablet
Amphetamine Salt Combo 7.5 mg tablet1.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6384020Yes2001-01-062021-01-06Us
USRE42096Yes1999-04-212019-04-21Us
US6605300Yes1999-04-212019-04-21Us
US6322819Yes1999-04-212019-04-21Us
USRE41148Yes1999-04-212019-04-21Us
US8062667No2009-03-292029-03-29Us
US8840924No2006-06-052026-06-05Us
US9017731No2012-06-282032-06-28Us
US8709491No2012-06-282032-06-28Us
US9265737No2012-06-282032-06-28Us
US8747902No2007-03-152027-03-15Us
US8597684No2007-03-152027-03-15Us
US8883217No2007-03-152027-03-15Us
US9675703No2007-03-152027-03-15Us
US9173857No2006-05-122026-05-12Us
US6913768No2003-05-242023-05-24Us
US8846100No2009-08-242029-08-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Volatizes slowly at room temperatureNot Available
water solubilitySlightlyNot Available
logP1.76HANSCH,C ET AL. (1995)
pKa10.1 (at 20 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility1.74 mg/mLALOGPS
logP1.85ALOGPS
logP1.8ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity43.71 m3·mol-1ChemAxon
Polarizability16.17 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.9565
Caco-2 permeable+0.8395
P-glycoprotein substrateNon-substrate0.7379
P-glycoprotein inhibitor INon-inhibitor0.9519
P-glycoprotein inhibitor IINon-inhibitor0.9859
Renal organic cation transporterNon-inhibitor0.8002
CYP450 2C9 substrateNon-substrate0.8114
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.795
CYP450 1A2 substrateNon-inhibitor0.5697
CYP450 2C9 inhibitorNon-inhibitor0.9313
CYP450 2D6 inhibitorInhibitor0.657
CYP450 2C19 inhibitorNon-inhibitor0.8445
CYP450 3A4 inhibitorNon-inhibitor0.8709
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8732
Ames testNon AMES toxic0.93
CarcinogenicityNon-carcinogens0.6869
BiodegradationNot ready biodegradable0.6575
Rat acute toxicity3.2491 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9452
hERG inhibition (predictor II)Non-inhibitor0.9231
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.59 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0006-9000000000-98cd0a725199f943d6cf
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014r-0900000000-8c26eef755113726e527
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0900000000-8cb9815fcd67a6b46f05
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-3900000000-5ec7b13e93ed8e0dc0b5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014u-3900000000-bbb73c900841d90c0ba1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9400000000-074f0f58bee23b3ea45a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9100000000-96e214b1c073232acc7e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-b6e1299382e4b38f6c4f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-2ed560c4c86538c3e790
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-6ddaf7d40e83a5c70c37
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014u-3900000000-5a23e52436daebe58716
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9500000000-f28704987cc3eacc8917
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9100000000-421879391d3453649aad
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-f8b71db6439096bac2b0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-270039c50b5f89d9c4ad
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-e84756122a0b431eee74
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-3900000000-20cdadf7c5b742c53087

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Aralkylamines / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Phenylpropane / Aralkylamine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Organonitrogen compound / Primary aliphatic amine / Amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amphetamines (CHEBI:2679)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles...
Gene Name
SLC18A2
Uniprot ID
Q05940
Uniprot Name
Synaptic vesicular amine transporter
Molecular Weight
55712.075 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  2. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. [PubMed:7751968]
  3. Teng L, Crooks PA, Dwoskin LP: Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J Neurochem. 1998 Jul;71(1):258-65. [PubMed:9648873]
  4. Eiden LE, Weihe E: VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci. 2011 Jan;1216:86-98. doi: 10.1111/j.1749-6632.2010.05906.x. [PubMed:21272013]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Negative modulator
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Lott DC, Kim SJ, Cook EH Jr, de Wit H: Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9. [PubMed:15602501]
  2. Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93. [PubMed:15661631]
  3. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11. [PubMed:15764732]
  4. Garcia BG, Wei Y, Moron JA, Lin RZ, Javitch JA, Galli A: Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol. 2005 Jul;68(1):102-9. Epub 2005 Mar 28. [PubMed:15795321]
  5. Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Epub 2005 Jan 5. [PubMed:15950014]
  6. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22. [PubMed:15728379]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Not Available
Specific Function
Satiety factor closely associated with the actions of leptin and neuropeptide y; this anorectic peptide inhibits both normal and starvation-induced feeding and completely blocks the feeding respons...
Gene Name
CARTPT
Uniprot ID
Q16568
Uniprot Name
Cocaine- and amphetamine-regulated transcript protein
Molecular Weight
12828.975 Da
References
  1. Loos RJ, Rankinen T, Tremblay A, Perusse L, Chagnon Y, Bouchard C: Melanocortin-4 receptor gene and physical activity in the Quebec Family Study. Int J Obes (Lond). 2005 Apr;29(4):420-8. [PubMed:15597110]
  2. McAlister ED, Van Vugt DA: Effect of leptin administration versus re-feeding on hypothalamic neuropeptide gene expression in fasted male rats. Can J Physiol Pharmacol. 2004 Dec;82(12):1128-34. [PubMed:15644956]
  3. Muhlhausler BS, Adam CL, Marrocco EM, Findlay PA, Roberts CT, McFarlane JR, Kauter KG, McMillen IC: Impact of glucose infusion on the structural and functional characteristics of adipose tissue and on hypothalamic gene expression for appetite regulatory neuropeptides in the sheep fetus during late gestation. J Physiol. 2005 May 15;565(Pt 1):185-95. Epub 2005 Jan 20. [PubMed:15661821]
  4. Scruggs P, Lai CC, Scruggs JE, Dun NJ: Cocaine- and amphetamine-regulated transcript peptide potentiates spinal glutamatergic sympathoexcitation in anesthetized rats. Regul Pept. 2005 Apr 15;127(1-3):79-85. [PubMed:15680473]
  5. Oliveira VX Jr, Fazio MA, Miranda MT, da Silva JM, Bittencourt JC, Elias CF, Miranda A: Leptin fragments induce Fos immunoreactivity in rat hypothalamus. Regul Pept. 2005 Apr 15;127(1-3):123-32. [PubMed:15680478]
  6. Vicentic A, Lakatos A, Jones D: The CART receptors: background and recent advances. Peptides. 2006 Aug;27(8):1934-7. Epub 2006 May 19. [PubMed:16713658]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Trace-amine receptor activity
Specific Function
Receptor for trace amines, including beta-phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amin...
Gene Name
TAAR1
Uniprot ID
Q96RJ0
Uniprot Name
Trace amine-associated receptor 1
Molecular Weight
39091.34 Da
References
  1. Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK: Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol Exp Ther. 2007 Apr;321(1):178-86. Epub 2007 Jan 11. [PubMed:17218486]
  2. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM: Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007 Apr;321(1):116-27. Epub 2007 Jan 18. [PubMed:17234900]
  3. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP: The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39. Epub 2006 Dec 21. [PubMed:17212650]
  4. Xie Z, Miller GM: Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther. 2007 Apr;321(1):128-36. Epub 2007 Jan 18. [PubMed:17234899]
  5. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11. [PubMed:15764732]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Stimulator
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA: In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther. 2003 Oct;307(1):138-45. Epub 2003 Sep 3. [PubMed:12954796]
  2. Wall SC, Gu H, Rudnick G: Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol. 1995 Mar;47(3):544-50. [PubMed:7700252]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Leibowitz SF: Reciprocal hunger-regulating circuits involving alpha- and beta-adrenergic receptors located, respectively, in the ventromedial and lateral hypothalamus. Proc Natl Acad Sci U S A. 1970 Oct;67(2):1063-70. [PubMed:4399738]
  2. Reisine TD, U'Prichard DC, Wiech NL, Ursillo RC, Yamamura HI: Effects of combined administration of amphetamine and iprindole on brain adrenergic receptors. Brain Res. 1980 Apr 28;188(2):587-92. [PubMed:6245760]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Leibowitz SF: Reciprocal hunger-regulating circuits involving alpha- and beta-adrenergic receptors located, respectively, in the ventromedial and lateral hypothalamus. Proc Natl Acad Sci U S A. 1970 Oct;67(2):1063-70. [PubMed:4399738]
  2. Reisine TD, U'Prichard DC, Wiech NL, Ursillo RC, Yamamura HI: Effects of combined administration of amphetamine and iprindole on brain adrenergic receptors. Brain Res. 1980 Apr 28;188(2):587-92. [PubMed:6245760]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO, et al.: Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse. 1992 Mar;10(3):177-84. [PubMed:1532675]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Clarke DE, Lyles GA, Callingham BA: A comparison of cardiac and vascular clorgyline-resistant amine oxidase and monoamine oxidase. Inhibition by amphetamine, mexiletine and other drugs. Biochem Pharmacol. 1982 Jan 1;31(1):27-35. [PubMed:7059347]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98. [PubMed:17209801]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...

Components:
References
  1. Heal DJ, Smith SL, Gosden J, Nutt DJ: Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol. 2013 Jun;27(6):479-96. doi: 10.1177/0269881113482532. Epub 2013 Mar 28. [PubMed:23539642]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Not Available
Specific Function
Not Available
Gene Name
VMAT2
Uniprot ID
Q99870
Uniprot Name
Vesicle monoamine transporter type 2
Molecular Weight
17291.525 Da
References
  1. Heal DJ, Smith SL, Gosden J, Nutt DJ: Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol. 2013 Jun;27(6):479-96. doi: 10.1177/0269881113482532. Epub 2013 Mar 28. [PubMed:23539642]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM: Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12. [PubMed:9264312]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Siu EC, Tyndale RF: Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther. 2008 Mar;324(3):992-9. Epub 2007 Dec 7. [PubMed:18065502]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022]
  2. Zhu HJ, Appel DI, Grundemann D, Markowitz JS: Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9. doi: 10.1111/j.1471-4159.2010.06738.x. Epub 2010 Apr 6. [PubMed:20402963]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Wu X, Prasad PD, Leibach FH, Ganapathy V: cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95. [PubMed:9618255]
  2. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528]
  3. Rytting E, Audus KL: Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8. Epub 2004 Aug 17. [PubMed:15316089]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:16